Table_3_Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible Enterobacterales.docx

Purpose: The infection of carbapenem-resistant Enterobacterales (CRE) has become a major clinical and healthcare problem worldwide. The screening methods of CRE have been extensively developed but still need improving [e.g., tests with accurate and simple minimum inhibitory (MICs)]. In this study, the performance of the BD Phoenix NMIC-413 AST panel was evaluated against clinical CRE and carbapenem-susceptible Enterobacterales (CSE) in China. The panel was first evaluated in the Chinese clinical lab.Methods: Antimicrobial susceptibility testing of 303 clinical Enterobacterales isolates were conducted by broth microdilution (BMD), Phoenix NMIC-413 AST panel, and disk diffusion method for imipenem, ertapenem, and meropenem. Considering BMD is a gold standard, essential agreement (EA), categorical agreement (CA), minor error (MIE), major error (ME), and very major error (VME) were determined according to CLSI guidelines. CA and EA > 90%, ME

目的：碳青霉烯类耐药肠杆菌科细菌（CRE）的感染已成为全球范围内的重大临床及医疗保健问题。尽管针对CRE的筛查方法已得到广泛的发展，但仍需进一步完善[例如，具备精确与简便的最小抑菌浓度（MICs）的检测]。在本研究中，BD Phoenix NMIC-413 AST测试板在中国临床CRE及碳青霉烯类敏感肠杆菌科细菌（CSE）中的性能得到了评估。测试板首先在中国临床实验室进行了评估。方法：通过肉汤微量稀释法（BMD）、BD Phoenix NMIC-413 AST测试板和纸片扩散法对303例临床肠杆菌科细菌分离株进行抗菌敏感性测试。鉴于BMD是金标准，根据美国临床和实验室标准协会（CLSI）指南，确定了必需一致性（EA）、分类一致性（CA）、轻微误差（MIE）、主要误差（ME）及非常重大误差（VME）。CA和EA超过90%，ME